R&D Changing Faces: Pharma and biotech hires, August 2026 August brought another wave of leadership changes across biotech, pharma, and research organisations.
R&D Changing Faces: Pharma and biotech hires, June & July 2026 In June/July, companies continued to reshape their leadership teams in preparation for upcoming clinical, regulatory, and commercial milestones.
R&D Changing Faces: Pharma and biotech hires, May 2026 Looking back to May, the pharma and biotech sector saw a steady stream of senior leadership changes.
R&D Changing Faces: Pharma and biotech, April 2026 April didn’t see too much activity at the big pharmas, but saw plenty of executive movement at small and midsized biotechs.
R&D Changing Faces: Pharma and biotech, March 2026 A broad mix of senior leadership and scientific and commercial appointments shaped last month’s pharma and biotech hiring activity.
R&D Changing Faces: Pharma and biotech, February 2026 The pharmaceutical and biotech sectors have seen a flurry of executive movement this month.
News Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
